IPFA 3rd Asia Workshop on Plasma Quality and Supply

Report of Workshop 

IPFA continued its programme of regional meetings in Asia on Plasma Quality and Supply with its 3rd workshop in Kuala Lumpur, Malaysia and once again reflected the priority of IPFA to promote and support the increased collection of high quality plasma from national and regional communities as a critical step towards improving patient access to essential PDMPs. The meeting was co-organised with and hosted by Pusat Darah Negara (National Blood Centre).

This partnership ensured that the programme was relevant, instructive and informative for delegates from the country, the region and wider international colleagues. The meeting was attended by approximately 175 delegates from 26 countries – both from the Asia region and the wider international community.

Setting the Scene

We were particularly honoured to welcome Datuk Dr Noor Hisham Abdullah, Director-General of Health, Ministry of Health, Malaysia to open the meeting and for providing an insight into the national strategies for meeting patient needs for blood components and plasma products throughout Malaysia. The opening session further developed this theme with excellent overviews of the status of blood and plasma supply in Malaysia (Dr Noryati Abu Amin) and concluded with an informative and stimulating keynote presentation delivered by Dr Francoise Rossi (on behalf of Prof. Thierry Burnouf) on key technical and organisational issues to be considered in the field of plasma collection and fractionation. Planning for the supply of essential Plasma Derived Medicinal Products (PDMPs) must always be underpinned by an understanding of patient needs and local health care priorities. Speakers in Session 2 of the meeting addressed these issues from the perspective of care for patients with haemophilia and immunedeficiencies and also highlighting the continuing clinical importance of prothrombin complex and the escalating need for IVIG for non-immune indications. They highlighted the often major variations in product access and clinical use.

Quality and Compliance – Practical Issues and Considerations

Previous workshops have highlighted the critical importance of the development and implementation of quality systems and GMP compliance to meet strict international regulatory standards for ‘plasma for fractionation’ as a key step towards increased supply of plasma and PDMPs. It was appropriate therefore that the afternoon of day one was once again devoted to a series of presentations and debate on the necessary quality systems and culture in blood establishments to meet such goals – including regulatory perspectives, operational experiences and potential economic and cost saving benefits from effective quality management programmes.

Contributions from Industry

It is a tradition of IPFA meetings to include stakeholder industries in the planning and content of our meetings and this workshop was no exception. We are always grateful to industry for their sponsorship and support for our meetings but also for their contribution to the scientific programme which opened day two of the meeting with presentations from Abbott, Grifols and Merck on key technical developments and activities in their respective companies in support of programmes in the region.

Towards an Increased Plasma Supply

The remainder of the meeting (sessions 6,7 and 8) focused on Donor Recruitment, Plasma Collection, Screening Programmes and Strategic options for PDMP supply. We were delighted that the programme was able to include contributions describing local initiatives and also the experiences of organisations with well-established plasma collection programmes and strategies for PDMP supply. The sharing of such experiences is as always regarded as a key element of IPFA Plasma workshops and known to be highly appreciated by meeting participants.

Thanks and Acknowledgements

IPFA was privileged to be invited by the Pusat Darah Negara to hold this workshop in Kuala Lumpur and we sincerely thank them for hosting the meeting, contributing so enthusiastically and helpfully to its organization. IPFA has made many friends and new colleagues. As always we sincerely thank our industry sponsors for their support for the meeting – without which the meeting could not have taken place. Presentations to the meeting were consistently relevant, thoughtful, stimulating and generous in their sharing of ideas and experiences and we are as always very grateful for the time and effort spent by participants in making the meeting a success! Finally our important thanks to all delegates for attending and supporting the meeting.

Workshop presentations

As announced at the meeting the proceedings are publicly available on the IPFA website. Please see below.

This Workshop was kindly supported by:

  • Abbott
  • B-Medical Systems
  • Fujirebio
  • Grifols
  • Merck
  • Roche Diagnostics

Picture gallery

Event partner(s):

Corporate Partners

This event will be available for corporate sponsorship and will offer excellent exposure and networking opportunities. We expect about 200 delegates including experts from both the region and internationally. The structure of the meeting will allow time for discussion and interaction with all interested participants, including your own experts, should they wish to attend.

In addition the size and informal atmosphere of the meeting will facilitate dialogue with guest speakers and other delegates both in the meeting forum and during breaks and social events. We have identified a number of categories of sponsorship, to profile and represent your company.

We are pleased to invite you to become one of the corporate sponsors for this event. Please note that the various sponsorship items will be allocated on a “first come, first served” basis.

Should you wish to receive the Sponsorship Prospectus, please contact Ms Mooijekind or Ms Heil at the IPFA Secretariat or follow the link below.

 

Event partner(s):

Programme / Proceedings

With our sincere appreciation and thanks to you all for contributing and participating in the IPFA 3rd Asia Workshop and in particular to our speakers for agreeing to publish their presentations. Please double click on the title of the presentation you wish to view.

In case you encounter a difficulty in opening the individual presentations below, then please contact the IPFA Secretariat: info@ipfa.nl

DAY ONE – Wednesday 21 March 2018

Session 1
OPENING AND SETTING THE SCENE
Chair: Dr P. Strengers
  • Opening and Formal Opening - Dr P. Strengers, IPFA (the Netherlands) and Datuk Dr Noor Hisham Abdullah, Director-General of Health, Ministry of Health, Malaysia
  • Keynote Setting the Scene - Dr F. Rossi, IPFA (the Netherlands)
  • Current status of plasma/PDMP supply in Malaysia - Dr N. Abu Amin, Pusat Darah Negara (Malaysia), Presentation not available
Session 2
MEETING PATIENT NEEDS
Chairs: Dr A Verma and Dr P. Strengers
Session 3
DEVELOPMENT OF QUALITY SYSTEMS FOR BLOOD ESTABLISHEMENTS
Chair: Mr J. Vincini
Session 4
QUALITY MANAGEMENT
Chair: Dr P. Flanagan
  • National Regulatory Authority Milestone in Promoting GMP Compliance in Blood Establishment - Mr M.L. Bin Ibrahim, NPRA (Malaysia) - Presentation not available
  • Specific Requirements for Plasma for Fractionation - Dr P. Strengers, IPFA (the Netherlands)
  • Quality Management – A Risk Based Approach - Mr M.N. Mohamad Noor, NPRA (Malaysia) - Presentation not available

DAY TWO – Thursday 22 March 2018

Session 5
MANUFACTURER'S SESSION
Chair: Dr Robert Perry
  • Abbott - Biotin Interference - Impact on Laboratory Test Results and Patients - Dr S. Bhatnagar, Abbott - Presentation not available
  • Grifols - Introduction of web-based Good Manufacturing Practices (GMP) in Asia Pacific - Ms A. Cooray, Grifols Diagnostic Solutions (USA) - Presentation not available
  • Merck - Tangential Flow Filtration challenges and consideration for Plasma - Ms K. Chan, Merck (Singapore) - Presentation not available
Session 6
STRATEGIES FOR NATIONAL / REGIONAL SUPPLY OF PDMPs
Chair: Dr F. Rossi
  • Secure national supply – the Australian experience - Mr M. Stone, National Blood Authority (Australia)
  • Perspective of Asia Pacific Economic Cooperation (APEC) - Ms A. Cooray, Grifols Diagnostic Solutions (USA) - Presentation not available
  • Example from the region: The National Fractionation Programme in Thailand - Dr U. Charoonruangrit, the Thai Red Cross Society (Thailand) - Presentation not available
  • Setting up a fractionation facility - Mr M. Tsuda, Japan Blood Products Organization (Japan)
  • Panel Discussion
Session 7
DONOR RECRUITMENT AND PLASMA SELECTION
Chair: Dr B. Perry
Session 8
EPIDEMIOLOGICAL CONSIDERATIONS AND DONOR SCREENING STRATEGIES
Chair: Dr P. Strengers
Session 9
CLOSURE
  • Closure - Dr B. Perry, International Plasma and Fractionation Association (the Netherlands)

Contact

International Plasma and Fractionation Association (IPFA)

Ms Mariska Mooijekind – congress organiser
Ms Linda Heil – assistant congress organiser

T. +31 (0)20 – 512 3561
info@ipfa.nl